Mostrar el registro sencillo del ítem

dc.contributor.author Rivero, Ezequiel Mariano
dc.contributor.author Perez, Cecilia
dc.contributor.author Gargiulo, Lucía
dc.contributor.author Entschladen, Frank
dc.contributor.author Zänker, Kurt
dc.contributor.author Bruzzone, Ariana
dc.contributor.author Luthy, Isabel Alicia
dc.date.available 2017-09-18T19:54:17Z
dc.date.issued 2017
dc.identifier.citation Rivero, Ezequiel Mariano; Perez, Cecilia; Gargiulo, Lucía; Entschladen, Frank; Zänker, Kurt; et al.; The β2-adrenergic agonist salbutamol inhibits migration, invasion and metastasis of the human breast cancer MDA-MB-231 cell line; Bentham Science Publishers; Current Cancer Drug Targets; 17; -1-2017; 1-14
dc.identifier.issn 1568-0096
dc.identifier.uri http://hdl.handle.net/11336/24518
dc.description.abstract Background: Breast cancer is the most diagnosed and the major cause of cancer death in women worldwide. Metastasis is the main cause of these deaths. The metastatic cascade involves multiple steps and it has been described that adrenergic receptors can modulate this process at multiple levels. However, β-adrenergic action in breast cancer is controversial. We have previously shown that β-adrenergic agonists inhibit cell proliferation and tumor growth of numerous breast cancer models. Objective: The purpose of the present investigation was to evaluate adrenergic effect in parameters related to tumor progression (migration, invasion and metastases) in two human breast cancer cell lines. Method: Migration was assessed in IBH-6 and MDA-MB-231 cells by time-lapse videomicroscopy and modified Boyden chambers. Invasion was evaluated by Transwells coated with Matrigel and expression of pro-metastatic genes was determined by RT-qPCR. Experimental metastases studies were performed by injection of the cells in the tail vein of NSG immuno-deficient mice. Results: In both cell lines, salbutamol (β2-agonist) and propranolol (β-blocker) significantly diminished cell migration while epinephrine exerted opposite effects. Moreover, salbutamol inhibited invasion of both breast cancer cell lines and enhanced adhesion to extracellular matrix. Salbutamol treatment was also able to decrease the expression of pro-metastatic genes in MDA-MB-231 cells. Finally, this compound decreased the number and size of MDA-MB-231 lung experimental metastases in NSG immuno- deficient mice. No effect on the establishment of IBH-6 metastases was observed. Conclusion: Our results suggest that salbutamol could be an effective adjuvant drug for the treatment of metastatic breast cancer.
dc.format application/pdf
dc.language.iso eng
dc.publisher Bentham Science Publishers
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject BREAST CANCER
dc.subject METASTASIS
dc.subject ADRENOCEPTORS
dc.subject SALBUTAMOL
dc.subject MDA-MB-231
dc.subject IBH-6
dc.subject.classification Bioquímica y Biología Molecular
dc.subject.classification Medicina Básica
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.subject.classification Patología
dc.subject.classification Medicina Básica
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.title The β2-adrenergic agonist salbutamol inhibits migration, invasion and metastasis of the human breast cancer MDA-MB-231 cell line
dc.type info:eu-repo/semantics/article
dc.type info:ar-repo/semantics/artículo
dc.type info:eu-repo/semantics/publishedVersion
dc.date.updated 2017-09-06T19:37:54Z
dc.identifier.eissn 1873-5576
dc.journal.volume 17
dc.journal.pagination 1-14
dc.journal.pais Emiratos Árabes Unidos
dc.conicet.avisoEditorial El manuscrito publicado está disponible en EurekaSelect a través de http://www.eurekaselect.com/openurl/content.php?genre%20=%20article%20&%20doi%20=10.2174/1568009617666170330151415
dc.description.fil Fil: Rivero, Ezequiel Mariano. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil Fil: Perez, Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil Fil: Gargiulo, Lucía. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil Fil: Entschladen, Frank. Witten/Herdecke University; Alemania
dc.description.fil Fil: Zänker, Kurt. Witten/herdecke University; Alemania
dc.description.fil Fil: Bruzzone, Ariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Investigaciones Bioquímicas de Bahía Blanca. Universidad Nacional del Sur. Instituto de Investigaciones Bioquímicas de Bahía Blanca; Argentina
dc.description.fil Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.journal.title Current Cancer Drug Targets
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/151233/article
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2174/1568009617666170330151415


Archivos asociados

Icon
Blocked Acceso no disponible

Aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)